Acadia Q2 revenue up 16% to $308M; raises FY2026 guidance to $1.24-1.30B

ACADIA PHARMACEUTICALS INC

DAYBUE net sales $125M (+30% YoY); NUPLAZID net sales $183M (+10% adj. YoY).
Full-year 2026 total revenue guidance raised to $1.24-1.30B; DAYBUE guidance raised to $480-510M.
Phase 2 remlifanserin topline results for Alzheimer's disease psychosis expected Sept-Oct 2026.
CHMP positive opinion for DAYBUE in EU for Rett syndrome; FDA Fast Track for remlifanserin.
CEO reaffirms long-term ambition of ~$1.7B annual net sales by 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.